Chief Commercial Officer (11) · ORAMED PHARMACEUTICALS INC. (ORMP)

Michael Rabinowitz

FY2021 is the first fiscal year CompBrief holds for Michael Rabinowitz as a named executive officer of ORAMED PHARMACEUTICALS; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$1,876,783

Salary $30,015Stock awards $986,352

3rd of 5 named executive officers at Oramed Pharmaceuticals by FY2021 total.

5 named officers on file for ORAMED PHARMACEUTICALS, FY2021

Michael Rabinowitz’s pay file — $29

  • 1 fiscal year of pay, line by line
  • ORMP’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how ORAMED PHARMACEUTICALS’s whole pay program stands against its peers

  • ORAMED PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ORMP→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed June 2, 2022 (DEF 14A).

Free

Get Michael Rabinowitz’s full pay file as a PDF — free

More than this page: up to 10 years of Michael’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Michael Rabinowitz compensation by year

ORAMED PHARMACEUTICALS Summary Compensation Table · the one fiscal year held
In US dollars, as ORAMED PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021
Salary$30,015
Bonus$0
Stock awards$986,352
Option awards$860,416
Non-equity incentive$0
Pension and deferred compensation$0
All other$0
Total$1,876,783

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ORAMED PHARMACEUTICALS INC. DEF 14A filed June 2, 2022, accession 0001213900-22-030956, and prior-year filings. Open the filing on EDGAR.

How this page was built: the ORAMED PHARMACEUTICALS INC. filed document, accession 0001213900-22-030956. Every figure is read from that document and cited to the page and table it appears in. Filed June 2, 2022.

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
RSU66,667$952,005—
Option87,500—$15.10

Per the Outstanding Equity Awards at Fiscal Year-End table in ORAMED PHARMACEUTICALS INC.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

ORAMED PHARMACEUTICALS’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Nadav KidronPresident, Chief Executive Officer and director (7)$4,020,581
Miriam KidronChief Scientific Officer and director (8)$2,334,974
Michael Rabinowitz · this pageChief Commercial Officer (11)$1,876,783
Joshua HexterChief Operating & Business Officer (10)$1,284,389
David SilbermanChief Financial Officer (9)$32,138

The full ORAMED PHARMACEUTICALS compensation record

free company brief

This page is one person within ORAMED PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the ORAMED PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ORAMED PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Michael Rabinowitz's compensation dossier · One-time report. No refunds.